Mr. Thomas Lynch Elected as Chairman of ICON plc
2012年12月22日 - 2:30AM
ビジネスワイヤ(英語)
ICON plc, (NASDAQ: ICLR)(ISIN: IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that,
Mr. Thomas Lynch has been appointed as Chairman of the board of
ICON plc with effect from 1st January 2013.
Mr. Lynch has served as a Non-Executive Director of ICON since
January 1996 and as Chairman of its Audit, Compensation and
Nominations Committees as well as Lead Independent Director since
December 2009.
Mr. Lynch served as Chairman and Chief Executive Officer of
Amarin Corporation from December 2007 through December 2009 during
which time he re-purposed and refinanced the company toward the
development of Vascepa for hypertriglyceridemia and dislipidemia.
Mr Lynch retired from the Board of Amarin in October 2010 but
continues as Chairman of Amarin Pharmaceuticals Ireland Ltd.
Mr. Lynch served in a variety of senior roles in Elan
Corporation plc from 1993 to 2004. He was a director of IDA Ireland
from 2001-2010 and of the Royal Opera House (Covent Garden) from
2001-2010. He currently serves as a director of GW Phamaceuticals
plc, is Chairman of Dublin Academic Medical Centre (an academic
health science centre incorporating the College of Health Sciences
UCD Dublin, St Vincent’s Hospital Group and the Mater Misericordiae
University Hospital); and the Queens University of Belfast
Foundation. He also serves as a board member of a number of public
and privately held pharmaceutical companies.
Mr. Lynch commented, “I am very pleased to assume the role of
Chairman at this time of great opportunity for ICON. I would
like to thank Dr. Bruce Given, my predecessor, for his contribution
as Chairman over the last three years. I look forward to working
with my Board colleagues and the executive team to help ICON
continue to grow and enhance its position as the global partner of
choice in the CRO industry.”
The information contained in this release is as of 21st December
2012. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to
ICON and its business can be found in ICON’s Annual Report for the
fiscal year ended December 31, 2011 and in the forms filed with the
US Securities and Exchange Commission, including the Forms 20-F,
F-1, S-8 and F-3. ICON disclaims any intent or obligation to update
these forward-looking statements.
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently operates from 82
locations in 40 countries and has approximately 9,430 employees.
Further information is available at www.iconplc.com.
ICON/ICLR-F
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024